DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01.
Edward J JarmanMarta Horcas-LopezScott H WaddellStephanie MacMasterKonstantinos GournopanosDaniel Y H SoongKamila I MusialikPanagiota TsokkouMinn-E NgWilliam A CambridgeDavid H WilsonMichael H KageyWalter NewmanJeffery W PollardLuke BoulterPublished in: Liver international : official journal of the International Association for the Study of the Liver (2022)
DKK1 promotes tumour immune evasion in iCCA through the recruitment of immune suppressive macrophages. Targeting DKK1 with a neutralizing antibody is effective at reducing tumour growth in vivo. As such, DKK1 targeted and immune modulatory therapies may be an effective strategy in iCCA patients with high DKK1 tumour expression or tolerogenic immune phenotypes.